Clinical trials: Rebound Therapy
- Condition Rebound Therapy
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Myopia
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
The objective of this clinical trial is to collect data on the rebound effect and long-term safety of SAT-001, a Software as a Medical Device (SaMD) under development for the inhibition and treatment of myopia progression in…
- Trial name
- NCT06742268
- Testing
- Single vision spectacles
- Where
- 5 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- S-Alpha Therapeutics, Inc.
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer
Myopia
Sustained Effect of Red-light Therapy for Myopia Control: A 2-Year Post-Trial Follow-up Study
To evaluate the long-term efficacy and safety of red-light therapy for myopia control over 2 years, and the potential rebound effect after treatment cessation.
- Trial name
- NCT06232161
- Testing
- Red-light therapy device, Spectacles
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beijing Airdoc Technology Co., Ltd.